# Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization

> **NCT00555971** · PHASE4 · COMPLETED · sponsor: **David Lang** · enrollment: 16 (actual)

## Conditions studied

- Aspirin Sensitivity

## Interventions

- **DRUG:** Omalizumab
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00555971
- **Lead sponsor:** David Lang
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2020-11-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00555971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00555971, "Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00555971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*